Consistently, the STEP (Semaglutide Treatment Effect in People with Obesity) trial [22] demonstrated that after 68 weeks of semaglutide therapy in individuals who are overweight or obese, the average weight loss achieved was 14.9%, with 86.4% of participants achieving a reduction of at least 5% from baseline, and 69.1% and 50.5% achieving reductions exceeding 10% and 15%, respectively
And protein choices matter, too
Discard any vial showing cloudiness, particulates, or signs of contamination
They can help determine if it is a true allergy
Understanding this fundamental difference is essential for patients and healthcare professionals when considering treatment options and managing expectations regarding therapeutic effects and potential side effects
Beyond medical monitoring, you can take several steps to protect your eye health while on GLP-1 therapy